The future of dry eye treatment with NTC's Imperial product line. Developed in partnership with Silgan Dispensing Systems, Imperial offers superior performance and convenience for patients.
 |
| NTC's commitment to innovation shines through in the launch of Imperial, a revolutionary eye drop solution designed to address the needs of patients suffering from dry eye disease. Riccardo Carbucicchio. Image: NTC |
Milan, Italy - October 7, 2024:
NTC, a leading international pharmaceutical company, has unveiled its groundbreaking new eye drop product line, Imperial. Developed in partnership with Silgan Dispensing Systems, Imperial leverages the innovative Iridya technology, a preservative-free multi-dose eye dropper. This strategic collaboration marks a significant step forward in addressing the needs of patients suffering from dry eye disease.
The Imperial product line is designed to provide patients with a superior experience. Its exceptional drop control ensures precise dosing, while the extended tip enhances accuracy during instillation. The ergonomic design minimizes extrusion force, making it comfortable and easy to use.
Marcello Selvaggio, NTC Global Head Ophthalmology, expressed his enthusiasm for the launch, stating, "Thanks to Iridya, we are elevating our innovative dry eye portfolio and aiming for maximum patient satisfaction and compliance." He emphasized the product's unique combination of benefits, drawing from the strengths of other leading preservative-free multi-dose devices.
The partnership with Silgan Dispensing Systems has been instrumental in bringing the Imperial product line to market. Riccardo Carbucicchio, CEO of NTC, highlighted the company's commitment to innovation and its focus on addressing unmet medical needs. He emphasized that Imperial's products will significantly improve the dry eye patient experience.
Eric Demaris, Commercial Director EMEA Silgan Dispensing Healthcare, expressed his excitement about the collaboration with NTC. He praised NTC's leadership in the ophthalmic market and emphasized the potential of Iridya technology in providing safer and more effective dry eye treatment.
NTC's research and development efforts are centered on making innovations accessible to everyone. By considering people's daily care needs and application habits, the company strives to increase the potential of its products. The Imperial product line is a testament to NTC's longstanding commitment to improving the experience and practice of care.
With Imperial, NTC aims to empower patients by giving them more control over their treatment. By enhancing compliance, the company hopes to contribute to better overall outcomes for patients with dry eye disease.